Video Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Non-Small Cell Lung Cancer

Featuring perspectives from Dr Edward B Garon, Dr John V Heymach, Dr Corey J Langer, Dr Ticiana Leal, Dr David R Spigel and Dr Helena Yu, including the following topics:

• Incorporation of Immunotherapeutic Strategies into the Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC)
  • Introduction (0:00)
  • Strategies to cope with platinum shortages (3:11)
  • Selection of appropriate candidates for neoadjuvant chemoimmunotherapy (5:51)
  • Current clinical role of adjuvant anti-PD-1/PD-L1 antibodies (11:03)
  • Patient selection for and practical implementation of consolidation durvalumab (15:40)
  • Faculty presentation: Dr Heymach (18:05)
• Contemporary Treatment for Localized or Metastatic NSCLC with an EGFR Mutation
  • Adjuvant osimertinib for EGFR mutation-positive localized NSCLC (29:45)
  • Potential implications of FLAURA2 (35:43)
  • Promising investigational strategies for progressive EGFR-mutant disease (38:15)
  • Sequencing of therapies for metastatic NSCLC with EGFR exon 20 insertion mutations (42:01)
  • Faculty presentation: Dr Yu (46:07)
• Research Advances Shaping the Current and Future Treatment of Metastatic NSCLC with ALK Rearrangements, ROS1 Rearrangements or RET Fusions
  • Selection of first- and later-line treatment for ALK-rearranged NSCLC (54:36)
  • Role of RET-targeted therapy in current clinical practice (56:53)
  • Selection of therapy for ROS1-positive NSCLC, including for patients with CNS involvement (59:30)
  • Faculty presentation: Dr Langer (1:01:25)
• Targeting MET, HER2 and KRAS Alterations in NSCLC
  • Current clinical role of trastuzumab deruxtecan in NSCLC (1:16:14)
  • Therapeutic sequencing for NSCLC with KRAS G12C mutations (1:20:41)
  • Management of MET exon 14 mutation-positive NSCLC (1:24:33)
  • Faculty presentation: Dr Spigel (1:29:36)
• Current Management of Metastatic NSCLC without a Targetable Tumor Mutation
  • Anti-PD-1/PD-L1 antibodies for patients for whom biomarker testing is pending (1:38:48)
  • Selection of first-line therapy for newly diagnosed metastatic NSCLC without a targetable tumor mutation (1:41:13)
  • Role of first-line immunotherapy in PD-L1-negative metastatic NSCLC (1:44:17)
  • Implications of antibiotic use and autoimmune toxicity for checkpoint inhibitor efficacy (1:48:15)
  • Faculty presentation: Dr Garon (1:53:41)
• Future Directions in the Management of Metastatic NSCLC
  • Future directions in NSCLC: Tumor treating fields and datopotamab deruxtecan (2:04:14)
  • Faculty presentation: Dr Leal (2:13:18)

CME information and select publications